Christoph Neumann-Haefelin
Overview
Explore the profile of Christoph Neumann-Haefelin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
3400
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kasper P, Neumann-Haefelin C, Allo G
Gastroenterology
. 2025 Mar;
PMID: 40057132
No abstract available.
2.
Stegmann S, Vohlen C, Im N, Niehues J, Selle J, Janoschek R, et al.
Sci Rep
. 2025 Feb;
15(1):6416.
PMID: 39984579
Perinatal obesity is associated with an increased risk of metabolic diseases and hepatic dysfunction in offspring. However, the underlying mechanisms of this metabolic programming remain incompletely understood. This study aimed...
3.
Martin A, Lang S, Schifferdecker F, Allo G, Chon S, Neumann-Haefelin C, et al.
J Hypertens
. 2025 Feb;
PMID: 39945743
Backgroundaims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for cardiovascular morbidity and mortality. Another critical risk factor in these patients is arterial hypertension (AH). Although it...
4.
Schafer N, Rothhaar P, Heuss C, Neumann-Haefelin C, Thimme R, Dietz J, et al.
Viruses
. 2025 Jan;
16(12.
PMID: 39772180
The study of hepatitis C virus (HCV) replication in cell culture is mainly based on cloned viral isolates requiring adaptation for efficient replication in Huh7 hepatoma cells. The analysis of...
5.
Zhang Z, Langenbach M, Sagar S, Fetsch V, Stritzker J, Severa E, et al.
Nat Immunol
. 2024 Dec;
26(1):92-104.
PMID: 39702858
The mechanisms underlying the efficacy of anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) therapy are incompletely understood. Here, by immune profiling responding PD-1CD8 T...
6.
Shoumariyeh K, Csernalabics B, Salimi Alizei E, Reinscheid M, Giese S, Ciminski K, et al.
Vaccines (Basel)
. 2024 Nov;
12(11).
PMID: 39591152
Background: Multiple myeloma (MM) patients are at high risk of severe infections including COVID-19 due to an immune dysregulation affecting both innate and adaptive immune responses. However, our understanding of...
7.
Schwarz T, Ptok J, Damagnez M, Menne C, Salimi Alizei E, Lang-Meli J, et al.
J Hepatol
. 2024 Nov;
PMID: 39536821
Background & Aims: Immune responses by CD8 T cells are essential for control of HBV replication. Although selection of escape mutations in CD8 T-cell epitopes has been previously described in...
8.
Heim K, Sagar , Sogukpinar O, Llewellyn-Lacey S, Price D, Emmerich F, et al.
Nat Immunol
. 2024 Aug;
25(9):1650-1662.
PMID: 39198634
Hepatitis B virus (HBV)-specific CD8 T cells play a dominant role during acute-resolving HBV infection but are functionally impaired during chronic HBV infection in humans. These functional deficits have been...
9.
Rusignuolo G, Thimme R, Neumann-Haefelin C
Dtsch Med Wochenschr
. 2024 Aug;
149(16):948-954.
PMID: 39094599
About 0,5% of the population in Germany has a chronic hepatitis B virus (HBV) infection. Untreated, chronic HBV infection can progress to liver cirrhosis and hepatocellular carcinoma (HCC). If diagnosed...
10.
Thimme R, Neumann-Haefelin C
Dtsch Med Wochenschr
. 2024 Aug;
149(16):929.
PMID: 39094596
No abstract available.